Skip to main content
KARD $12.69 +3.00%
KARD logo
KARD · Kardigan, Inc.
Track KARD — free
$12.69 +0.37 (+3.00%)
Market Cap
$1.15B
Shares
93.60M
Volume · Nov 19 543.57K Avg daily vol (3M) 603.96K
All webcasts

Earnings call · FY2026 Q3

Kardigan, Inc. (KARD) Q3 2026 Earnings Call

Concluded Nov 12, 2026
Nov 12, 2026
Period
FY2026 Q3
Runtime
—
Sources
2 artifacts
Diluted EPS -$0.64
Net income -$58.57M
Open full screen 8-K 10-Q

Executive readout · one minute

What the filings say

8-K earnings release · filed Nov 12, 2026
Kardigan completed enrollment in Cohort 2 of the Phase 2b danicamtiv KINSHIP-DCM trial, with topline data expected in 2Q 2027; it also completed ataciguat KATALYST-AV Phase 2b enrollment, with data expected in 2H 2027. Cash was $591.4 million.
10-Q report · filed Nov 12, 2026
Kardigan advanced three late-stage programs—Danicamtiv, Ataciguat and Tonlamarsen—and expects clinical data in 2027. It reported $591.4 million in cash, cash equivalents and investments and a $230.9 million nine-month net loss.

The audio replay and transcript follow the call.

Research coverage

2 live sources

Open each available source without leaving this research workspace.

Research materials

Open the source you need; every reader stays inside this workspace.

Full-screen source Call document